125 results
Page 4 of 7
6-K
EX-99.1
kialhkqmubzvw5dq
18 Nov 14
Live Filing
12:00am
6-K
EX-99.1
1w2psmygug6 u5zfhjdc
7 Nov 14
Live Filing
12:00am
6-K
EX-99.1
0e433by dtg
8 Sep 14
Successful Completion of Phase Iii Program for Teva’s Reslizumab
12:00am
6-K
EX-99.1
j6q77poey0jd9clce qg
2 Sep 14
Live Filing
12:00am
6-K
EX-99.1
xu8571k0syv
14 Jul 14
First Breath-Actuated Dry-Powder SABA Inhaler to be Accepted by FDA for Review
12:00am
6-K
qkswq30rn5uecl
18 Jun 14
Current report (foreign)
12:00am
6-K
EX-99.1
6w4nj9b09tdo9s8gna
9 Jun 14
FDA Approves Expanded Label for AZILECT® for Treatment Across All Stages of Parkinson’s Disease
12:00am
6-K
EX-99.1
ezifburd5 ef6
24 Apr 14
Pride-hd Study Enrolling Patients Globally to Further Evaluate Pridopidine for the Symptomatic Treatment of Huntington’s Disease
12:00am
6-K
EX-99.1
yl45yz qvltn3ewn
3 Mar 14
The first and only orally inhaled medicine for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults
12:00am
6-K
l2u 6edxo
17 Jan 14
Current report (foreign)
12:00am
6-K
EX-99.1
rm6bfsgis 266r1ak1
27 Nov 13
Teva Announces Additional Regulatory Exclusivity for Treanda® (Bendamustine Hci) for Injection
12:00am
6-K
EX-99.1
48tb6xtztrnintoed
18 Nov 13
Teva Announces Updates to Oncology Biologic Portfolio
12:00am
6-K
EX-99.1
5mrp063l34
23 Sep 13
Teva Announces Favorable Court Ruling In Azilect® Patent Infringement Litigation Against Mylan
12:00am
6-K
EX-99.1
serjvp odvzpj3a6
17 Sep 13
Fda Approves Teva’s Treanda® (Bendamustine Hci) Injection, a New Liquid Formulation
12:00am
6-K
EX-32.1
hfinhpak96w3yeckg
12 Jun 13
Live Filing
12:00am
6-K
EX-99.1
hovee98
8 May 13
Adasuve® (loxapine) inhalation powder is approved in the U.S. for the acute treatment of agitation associated with schizophrenia and bipolar disorder
12:00am
6-K
EX-32.1
ezr6bkm3
6 May 13
Live Filing
12:00am
6-K
EX-99.1
tfse c9a4gcqc
29 Mar 13
Live Filing
12:00am